CA2685329A1 - Methods and compositions for promoting localization of pharmaceutically active agents to bone - Google Patents

Methods and compositions for promoting localization of pharmaceutically active agents to bone Download PDF

Info

Publication number
CA2685329A1
CA2685329A1 CA002685329A CA2685329A CA2685329A1 CA 2685329 A1 CA2685329 A1 CA 2685329A1 CA 002685329 A CA002685329 A CA 002685329A CA 2685329 A CA2685329 A CA 2685329A CA 2685329 A1 CA2685329 A1 CA 2685329A1
Authority
CA
Canada
Prior art keywords
bone
peptide
amino acid
binding domain
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002685329A
Other languages
English (en)
French (fr)
Inventor
Hanne Gron
David Duffin
Doug Buechter
Elliott Gruskin
Michael Lehmicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthes USA LLC
Affinergy Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2685329A1 publication Critical patent/CA2685329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
CA002685329A 2007-04-27 2008-04-23 Methods and compositions for promoting localization of pharmaceutically active agents to bone Abandoned CA2685329A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91434107P 2007-04-27 2007-04-27
US60/914,341 2007-04-27
US12/107,098 2008-04-22
US12/107,098 US7977313B2 (en) 2007-04-27 2008-04-22 Methods and compositions for promoting localization of pharmaceutically active agents to bone
PCT/US2008/061200 WO2008134329A1 (en) 2007-04-27 2008-04-23 Methods and compositions for promoting localization of pharmaceutically active agents to bone

Publications (1)

Publication Number Publication Date
CA2685329A1 true CA2685329A1 (en) 2008-11-06

Family

ID=39887259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002685329A Abandoned CA2685329A1 (en) 2007-04-27 2008-04-23 Methods and compositions for promoting localization of pharmaceutically active agents to bone

Country Status (6)

Country Link
US (1) US7977313B2 (https=)
EP (1) EP2152075A4 (https=)
JP (2) JP2011500104A (https=)
CN (1) CN101668422A (https=)
CA (1) CA2685329A1 (https=)
WO (2) WO2008133886A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827564A (zh) 2007-09-04 2010-09-08 阿费内基有限公司 用于将生长因子递送至纤维结缔组织的方法和组合物
US8629106B2 (en) * 2010-03-16 2014-01-14 Janssen Biotech, Inc. Affinity peptides toward BMP-2
JP6302756B2 (ja) * 2014-06-06 2018-03-28 シスメックス株式会社 細胞の回収方法及びその方法に用いられる加工骨
EP3341397B1 (en) 2015-08-25 2024-12-18 Histide AG Compounds for inducing tissue formation and uses thereof
IL298067A (en) 2015-08-25 2023-01-01 Histide Ag Compounds for inducing tissue formation and their uses
JP6890836B2 (ja) 2015-09-17 2021-06-18 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
US11834517B2 (en) 2017-09-18 2023-12-05 Brandeis University Branched peptides for enzymatic assembly and mitochondria drug delivery
WO2019055988A1 (en) * 2017-09-18 2019-03-21 Brandeis University BRANCHED PEPTIDES FOR ENZYMATIC ASSEMBLY AND DRUG DELIVERY TO MITOCHONDRIA
WO2020041312A1 (en) * 2018-08-20 2020-02-27 Alliance For Sustainable Energy, Llc Cellulose nanofiber biomaterial
WO2020077265A1 (en) 2018-10-12 2020-04-16 Theradaptive, Inc. Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
US20240158441A1 (en) * 2020-03-18 2024-05-16 Brandeis University Branched peptides for enzymatic assembly and mitochondria drug delivery
BR112022020809A2 (pt) 2020-04-15 2023-02-23 Theradaptive Inc Composições e métodos para entrega terapêutica direcionada ao osso

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6395253B2 (en) * 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
AU2003213246A1 (en) * 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
JP2005185101A (ja) * 2002-05-30 2005-07-14 National Institute Of Agrobiological Sciences 植物の全長ｃＤＮＡおよびその利用
US7238669B2 (en) * 2002-09-11 2007-07-03 The Curators Of The University Of Missouri Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7163920B2 (en) * 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US8188219B2 (en) * 2004-01-28 2012-05-29 The Regents Of The University Of California Bone morphogenic protein binding peptide
ATE462451T1 (de) * 2004-06-16 2010-04-15 Affinergy Inc Grenzflächenbiomaterialien zur förderung der anhaftung von zielanalyten
WO2006052840A2 (en) * 2004-11-04 2006-05-18 University Of Virginia Patent Foundation Bone tropic peptides
WO2006048877A2 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of b-cell malignancies with fgfr3 inhibitors
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices

Also Published As

Publication number Publication date
US20080268015A1 (en) 2008-10-30
WO2008134329A1 (en) 2008-11-06
US7977313B2 (en) 2011-07-12
EP2152075A4 (en) 2011-01-26
EP2152075A1 (en) 2010-02-17
JP2013151561A (ja) 2013-08-08
WO2008133886A1 (en) 2008-11-06
CN101668422A (zh) 2010-03-10
JP2011500104A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
US7977313B2 (en) Methods and compositions for promoting localization of pharmaceutically active agents to bone
US20080015138A1 (en) Metal binding compounds, metal binding compositions, and their uses
JP2011500104A5 (https=)
US7994277B2 (en) IFBM's to promote the specific attachment of target analytes to the surface of orthopedic implants
WO2007081943A2 (en) Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
US8067021B2 (en) Methods and compositions for delivery of growth factor to fibrous connective tissue
US20210369812A1 (en) Osteoinductive peptides, compositions, implants, and methods of use
CA2742202A1 (en) Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130409

FZDE Discontinued

Effective date: 20151201